Ingrezza, valbenazine
Named-patient access overview. Ingrezza is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice.
About Ingrezza
Ingrezza (valbenazine) is an oral, once-daily selective inhibitor of vesicular monoamine transporter 2 (VMAT2), manufactured by Neurocrine Biosciences. It was the first VMAT2 inhibitor approved by the US FDA for adults with tardive dyskinesia and is also approved for chorea associated with Huntington's disease. Ingrezza works by reducing the presynaptic release of dopamine, dampening the involuntary movements characteristic of these neurologic conditions.
Ingrezza is supplied as 40 mg, 60 mg, and 80 mg capsules. It is taken once daily by mouth, with or without food, and is generally titrated to the dose that balances symptom control with tolerability. Because Ingrezza is stored at room temperature, it does not require cold-chain handling in transit, which simplifies international shipment.
For international patients whose home-country formulary either does not list Ingrezza or lists it with restrictive coverage rules, a US-sourced named-patient pathway is often the most practical route to consistent, on-label therapy.
Who Ingrezza is for
Ingrezza is generally considered for adults with tardive dyskinesia, particularly those whose involuntary movements persist despite adjustments to the underlying antipsychotic regimen, and for adults with chorea associated with Huntington's disease. The treating neurologist or psychiatrist weighs the severity of involuntary movements, comorbid conditions, the underlying psychiatric or neurologic diagnosis, and other treatment options before initiating Ingrezza. The prescriber should monitor for sleepiness, prolongation of the QT interval, and Parkinsonism, in line with the manufacturer's prescribing information.
How Reserve Meds coordinates Ingrezza
- Patient or treating physician submits a named-patient request through Reserve Meds intake.
- Our clinical team verifies appropriateness of Ingrezza for the patient's diagnosis and destination country.
- The treating physician issues a prescription and a brief clinical justification.
- Country-specific named-patient program or personal-import documentation is prepared.
- Ingrezza is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician, hospital pharmacy, or approved address, with quantity sized to the prescribed dosing interval.
Pricing and what shapes it
Ingrezza's landed price for international patients is shaped by the wholesale acquisition cost in the United States, destination-country import duties and value-added tax, logistics fees, and the Reserve Meds coordination fee. The cost scales with the prescribed daily dose and the cycle length covered. Once intake is complete and the destination confirmed, our coordinator issues a firm written quote covering the full landed cost before any wire is requested.
Timing expectations
From a complete intake, indicative timing for Ingrezza to reach a patient in our priority markets ranges from approximately two to five weeks. The dominant variables are destination-country regulatory processing, completeness of the physician package, and customs clearance. Because Ingrezza is an oral capsule at ambient temperature, transit risk is lower than for refrigerated biologics. Reserve Meds assigns each case a single named coordinator who maintains continuity from intake through delivery and refill.
Access by country
Reserve Meds publishes a detailed country deep-dive for Ingrezza in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling. Tap any country to read the full deep-dive.
Storage and handling, in plain language
Ingrezza capsules are stable at room temperature in the original bottle. They should be kept dry, away from direct sunlight, and out of reach of children. There is no cold-chain requirement, which simplifies international transit. Reserve Meds packages each shipment with tamper-evident seals and documentation that matches the wholesaler's serial records, so the receiving physician can verify provenance on arrival.
Documentation the physician will be asked to provide
The typical package includes a current prescription, a brief clinical justification letter that describes the patient's tardive dyskinesia or Huntington's chorea presentation and prior management, a copy of the physician's license, and the destination-country named-patient or personal-import form where applicable. Reserve Meds prepares the country-specific paperwork; the physician supplies the clinical pieces. We aim to keep the physician's workload to under thirty minutes per case.
Privacy and data handling
Patient information collected through Reserve Meds intake is handled under HIPAA standards in the United States and the privacy regimes that apply in the destination country, including UAE PDPL, KSA PDPL, India DPDPA, and the EU GDPR where relevant. We share only the minimum necessary information with the prescribing physician, the wholesaler, the carrier, and any regulator who requires submission.
Start a request for Ingrezza
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Reserved for you.